Cargando…

The EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) study programme: Design and exposure accrual for an evaluation of empagliflozin in routine clinical care

BACKGROUND: The EMPA‐REG OUTCOME trial showed that empagliflozin reduced the risk of cardiovascular death and hospitalization for heart failure (HHF) in diabetic patients with cardiovascular disease. EMPRISE is a study programme on the effectiveness, safety and healthcare utilization of empagliflozi...

Descripción completa

Detalles Bibliográficos
Autores principales:	Patorno, Elisabetta, Najafzadeh, Mehdi, Pawar, Ajinkya, Franklin, Jessica M., Déruaz‐Luyet, Anouk, Brodovicz, Kimberly G., Santiago Ortiz, Adrian J., Bessette, Lily G., Kulldorff, Martin, Schneeweiss, Sebastian
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	John Wiley and Sons Inc. 2019
Materias:	Original Research Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6947693/ https://www.ncbi.nlm.nih.gov/pubmed/31922030 http://dx.doi.org/10.1002/edm2.103

Ejemplares similares

Empagliflozin is associated with lower cardiovascular risk compared with dipeptidyl peptidase-4 inhibitors in adults with and without cardiovascular disease: EMPagliflozin compaRative effectIveness and SafEty (EMPRISE) study results from Europe and Asia
por: Vistisen, Dorte, et al.
Publicado: (2023)

Cardiovascular and renal effectiveness of empagliflozin in routine care in East Asia: Results from the EMPRISE East Asia study
por: Seino, Yutaka, et al.
Publicado: (2020)

Comparative Effectiveness of Empagliflozin vs Liraglutide or Sitagliptin in Older Adults With Diverse Patient Characteristics
por: Htoo, Phyo T., et al.
Publicado: (2022)

Empagliflozin is associated with lower risk of cardiovascular events and all‐cause mortality in routine care in East Asia: Results from the EMPRISE study
por: Kim, Dae Jung, et al.
Publicado: (2023)

Healthcare resource utilization in patients treated with empagliflozin in East Asia
por: Sheu, Wayne H‐H, et al.
Publicado: (2022)

Empagliflozin reduces cardiorenal events, healthcare resource use and mortality in Sweden compared to dipeptidyl peptidase‐4 inhibitors: Real world evidence from the Nordic EMPRISE study
por: Nyström, Thomas, et al.
Publicado: (2022)

L'emprise : roman /
por: Brulotte, Gaétan
Publicado: (1979)

Empagliflozin in type 1 diabetes
por: Mathieu, Chantal, et al.
Publicado: (2019)

Anti-inflammatory potential of Empagliflozin
por: Pirklbauer, Markus
Publicado: (2021)

Drug eruption associated with empagliflozin
por: Yau, Kevin, et al.
Publicado: (2022)

PREDICTOR: A Physical emulatoR enabling safEty anD ergonomICs evaluation and Training of physical human-rObot collaboRation
por: Sunesson, Carl Emil, et al.
Publicado: (2023)

Compás
por: Bonifaz, Marirrós, 1957-
Publicado: (2002)

Empagliflozin: Not just a glorified diuretic
por: John, Mathew
Publicado: (2016)

Impact of empagliflozin on diabetic kidney disease
por: Koya, Daisuke
Publicado: (2017)

Empagliflozin in Patients with Chronic Kidney Disease
por: Herrington, William G., et al.
Publicado: (2023)

Masked Primary Hyperparathyroidism by Empagliflozin Use
por: Awada, Mariam, et al.
Publicado: (2022)

Role of empagliflozin in chronic lithium toxicity
por: Dyson, Vicki
Publicado: (2022)

The Use of Empagliflozin Post Myocardial Infarction
por: Ravendran, Kapilraj, et al.
Publicado: (2023)

Empagliflozin: a potential anticancer drug
por: Wu, Wenwen, et al.
Publicado: (2023)

L'Emprise de l'organisation /
Publicado: (1998)

Empagliflozin: Novel antidiabetes and pro-cardiac drug
por: Raut, Monish S, et al.
Publicado: (2017)

Empagliflozin: Euglycaemic diabetic ketoacidosis: case report
Publicado: (2020)

Empagliflozin prevents doxorubicin-induced myocardial dysfunction
por: Sabatino, Jolanda, et al.
Publicado: (2020)

Empagliflozin: Euglycaemic diabetic ketoacidosis: case report
Publicado: (2022)

Empagliflozin: Euglycaemic diabetic ketoacidosis: case report
Publicado: (2021)

Empagliflozin: Euglycaemic diabetic ketoacidosis: case report
Publicado: (2021)

Economic Spectrofluorometric Bioanalysis of Empagliflozin in Rats' Plasma
por: Ayoub, Bassam, et al.
Publicado: (2021)

Association between Empagliflozin Use and Electrocardiographic Changes
por: Antwi-Amoabeng, Daniel, et al.
Publicado: (2022)

Empagliflozin in acute myocardial infarction: the EMMY trial( )
por: von Lewinski, Dirk, et al.
Publicado: (2022)

L'emprise des enfants entre nous /
por: Schérer, René
Publicado: (1979)

Incidence of lower extremity amputations among patients with type 1 and type 2 diabetes in the United States from 2010 to 2014
por: Déruaz‐Luyet, Anouk, et al.
Publicado: (2020)

Empagliflozin in the treatment of type 2 diabetes: evidence to date
por: Shubrook, Jay H, et al.
Publicado: (2015)

Myopathy secondary to empagliflozin therapy in type 2 diabetes
por: Gao, Frank, et al.
Publicado: (2020)

Empagliflozin: Euglycemic and hyperglycaemic diabetic ketoacidosis: case report
Publicado: (2021)

Empagliflozin: Euglycaemic diabetic ketoacidosis: 2 case reports
Publicado: (2021)

Empagliflozin/linagliptin: Euglycaemic diabetic ketoacidosis: case report
Publicado: (2021)

Effect of Empagliflozin on Sphingolipid Catabolism in Diabetic and Hypertensive Rats
por: Pérez-Villavicencio, Roxana, et al.
Publicado: (2022)

Cardioprotective effects of empagliflozin after ischemia and reperfusion in rats
por: Seefeldt, Jacob Marthinsen, et al.
Publicado: (2021)

Empagliflozin-Induced Pancreatitis: A Case Report Pattern
por: Foster, Parker, et al.
Publicado: (2022)

New Insights into the Use of Empagliflozin—A Comprehensive Review
por: Forycka, Joanna, et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_mc2slkeabb6emss86poffvgu02